WARRANT TO PURCHASE STOCKWarrant to Purchase Stock • April 9th, 2004 • Threshold Pharmaceuticals Inc • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
AMENDED AND RESTATED LEASE AGREEMENT BY AND BETWEEN HMS GATEWAY OFFICE L.P., a Delaware limited partnership AS LANDLORD and ADVANCED MEDICINE, INC., a Delaware corporation AS TENANT DATED January 1, 2001 Exhibit ALease Agreement • April 9th, 2004 • Threshold Pharmaceuticals Inc • California
THIS AMENDED AND RESTATED LEASE AGREEMENT is made and entered into by and between Landlord and Tenant as of the Lease Date.
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS Exclusive License AgreementExclusive License Agreement • April 9th, 2004 • Threshold Pharmaceuticals Inc
This exclusive license agreement (the “Agreement”) is by and between Threshold Pharmaceuticals, Inc., a California corporation having an address at 849 Mitten Road, Suite 104, Burlingame, CA 94010 (“Licensee”), and Dr. Theodore J. Lampidis, residing at 6995 South West 67th Ave., Miami, FL 33143, and Dr. Waldemar Priebe, residing at 4239 Emory St., Houston, TX 77005 (Dr. Lampidis and Dr. Priebe are collectively referred to herein as “Licensor”), and has an effective date of 11 November 2002 (the “Effective Date”).
SUBLEASESublease • April 9th, 2004 • Threshold Pharmaceuticals Inc
THIS SUBLEASE (“Sublease”) is dated for references purposes only as of December 5, 2002, and is entered by and between THERAVANCE, INC., a Delaware corporation (“Sublessor”), and THRESHOLD PHARMACEUTICALS, INC., a Delaware corporation (“Sublessee”). Sublessor and Sublessee hereby agree as follows:
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS AGREEMENT between THRESHOLD PHARMACEUTICALS INC. and BAXTER INTERNATIONAL...Licensing Agreement • April 9th, 2004 • Threshold Pharmaceuticals Inc • California
THRESHOLD Pharmaceuticals Inc., a corporation organized and existing under the laws of Delaware of the United States of America and having its head office at 951 Gateway Boulevard, Suite 3A, South San Francisco, CA 94080, United States of America (hereinafter referred to as “THRESHOLD”),
LOAN AND SECURITY AGREEMENT By and Between THRESHOLD PHARMACEUTICALS, INC. And SILICON VALLEY BANKLoan and Security Agreement • April 9th, 2004 • Threshold Pharmaceuticals Inc
This LOAN AND SECURITY AGREEMENT dated March 27, 2003, between SILICON VALLEY BANK (“Bank”), whose address is 3003 Tasman Drive, Santa Clara, California 95054 and THRESHOLD PHARMACEUTICALS, INC, a Delaware corporation (“Borrower”), whose address is 951 Gateway Boulevard, Suite 3A, South San Francisco, California 94080, provides the terms on which Bank will lend to Borrower and Borrower will repay Bank. The parties agree as follows:
THRESHOLD PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT November 17, 2003Investor Rights Agreement • April 9th, 2004 • Threshold Pharmaceuticals Inc • California
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 17th day of November, 2003, by and among THRESHOLD PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
